ConvaTec Group Plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jonathan Peter Mason
- Full Time Employees
- 10,910
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 20 Eastbourne Terrace London GL United Kingdom W2 6LG
- IPO Date
- Jan 26, 2017
- Website
- convatecgroup.com
- Similar Companies
- Business
- ConvaTec Group Plc (CTEC; CNVVY) develops, manufactures and markets medical products and technologies focused on therapies for chronic disease management; it offers advanced wound care solutions including dressings for acute and chronic wounds from conditions such as diabetes, trauma and burns; ostomy care products encompassing devices, accessories and services for stoma patients resulting from colorectal or bladder cancer, inflammatory bowel disease and trauma; continence care items for urinary issues linked to spinal cord injuries, neurological diseases and prostate enlargement; and infusion care comprising disposable sets for insulin pumps in diabetes treatment or continuous infusions for Parkinson's disease. The FTSE 100 company, founded in 1978 and headquartered at 7th Floor, 20 Eastbourne Terrace, London W2 6LG, United Kingdom, employs approximately 10,000 people and operates in more than 100 countries with net sales distributed across Europe/Middle East/Africa (29%), Americas (57%) and Asia/Pacific (15%). Recent developments include the July 2025 receipt of US FDA 510(k) clearance, CE mark, UKCA mark and Australian TGA approval for AQUACEL ConvaFiber, a next-generation wound care product; the August 2025 launch of a $300 million share buyback programme running through December 2025 to return surplus capital to shareholders; and the November 2025 secondary offering where institutional investors acquired a 7.8% stake from Novo Holdings for £351 million.
Company News
Convatec Expands Cure™ Portfolio With Launch of Cure Aqua™, Bringing Greater Choice to People Who Catheterize
Convatec Group PLC (CNVVY) Q2 2026 Earnings Call Transcript
ConvaTec Group H1 Earnings Call Highlights
UK's Convatec expects higher second-half margin, launches $200 million buyback
Convatec Group PLC (CNVVY) ConvaTec Group PLC, 4 Months Period Ending/ Trading Statement Call Transcript
Medical product maker Convatec warns of higher cost from Iran War
ConvaTec falls despite backing outlook
Convatec's Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 2026
Convatec Group PLC (CNVVY) Analyst/Investor Day Transcript
Leading bank sees Convatec investor meting as credibility test for growth targets
Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories
Convatec Group PLC (CNVVY) Q4 2025 Earnings Call Transcript
ConvaTec Group (OTCMKTS:CNVVY) Trading Up 1.6% – What’s Next?
Artisan International Small-Mid Fund Q3 2025 Performance Review
ConvaTec Group PLC (CNVVY) 10 Months 2025 Sales/ Trading Statement Call Transcript
ConvaTec Group PLC (CNVVF) Q2 2024 Earnings Call Transcript
ConvaTec Group PLC (CNVVF) Q4 2023 Earnings Call Transcript
ConvaTec Group Plc (CNVVF) CEO Karim Bitar on Q2 2022 Results - Earnings Call Transcript